We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-12.02%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$760M
AUM Growth
+$89.2M
Cap. Flow
+$192M
Cap. Flow %
25.21%
Top 10 Hldgs %
39.48%
Holding
222
New
36
Increased
135
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$9.39M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$8.96M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.48M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.63M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$10.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$6.27M
3
BIIB icon
Biogen
BIIB
+$6.18M
4
GOSS icon
Gossamer Bio
GOSS
+$3.78M
5
IBB icon
iShares Biotechnology ETF
IBB
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 42.6%
2 Consumer Staples 0.27%
3 Technology 0.24%
4 Financials 0.1%
5 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
51
Whitehawk Therapeutics
WHWK
$190M
$3.54M 0.47%
208,368
+11,960
+6% +$229K
INBX
52
DELISTED
Inhibrx, Inc. Common Stock
INBX
$3.52M 0.46%
157,842
+7,992
+5% +$204K
NTLA icon
53
Intellia Therapeutics
NTLA
$1.49B
$3.44M 0.45%
+47,408
New +$4.02M
AMLX icon
54
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
$3.21M 0.42%
+250,000
New +$5.65M
RETA
55
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.85M 0.37%
+86,905
New +$2.58M
AYLA
56
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$2.82M 0.37%
708,383
+39,112
+6% +$203K
LONA
57
PUT
LeonaBio Inc
LONA
$66.3M
$2.7M 0.36%
+20,000
New +$2.11M
STSA
58
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$2.48M 0.33%
653,448
+24,064
+4% +$108K
XFOR icon
59
X4 Pharmaceuticals
XFOR
$375M
$2.4M 0.32%
45,734
-29,749
-39% -$1.71M
PRDS
60
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.34M 0.31%
323,934
-76,066
-19% -$748K
ZLAB icon
61
CALL
Zai Lab
ZLAB
$2.06B
$2.34M 0.31%
53,100
+43,500
+453% +$2.1M
OVID icon
62
Ovid Therapeutics
OVID
$414M
$2.32M 0.3%
738,372
+33,290
+5% +$105K
SVRA icon
63
Savara
SVRA
$1.12B
$2.13M 0.28%
1,622,552
+82,861
+5% +$99.8K
KYMR icon
64
Kymera Therapeutics
KYMR
$8.51B
$2.12M 0.28%
+50,000
New +$2.11M
WVE icon
65
Wave Life Sciences
WVE
$1.09B
$2.1M 0.28%
1,048,039
+54,558
+5% +$134K
PMVP icon
66
CALL
PMV Pharmaceuticals
PMVP
$59.2M
$2.08M 0.27%
+100,000
New +$1.76M
PMVP icon
67
PUT
PMV Pharmaceuticals
PMVP
$59.2M
$2.08M 0.27%
+100,000
New +$1.76M
CABA icon
68
Cabaletta Bio
CABA
$437M
$2.07M 0.27%
1,020,070
+49,672
+5% +$130K
CNTB
69
Connect Biopharma Holdings
CNTB
$127M
$2.05M 0.27%
677,859
+415,622
+158% +$1.75M
CLNN icon
70
Clene
CLNN
$64M
$2.03M 0.27%
25,714
+1,248
+5% +$75.5K
INBX
71
CALL
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.91M 0.25%
85,800
+5,000
+6% +$128K
GOSS icon
72
CALL
Gossamer Bio
GOSS
$82.9M
$1.84M 0.24%
211,600
+11,600
+6% +$112K
LQDA icon
73
Liquidia Corp
LQDA
$7.48B
$1.75M 0.23%
243,904
-81,541
-25% -$513K
GBT
74
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.73M 0.23%
49,997
-114,085
-70% -$3.41M
LYRA
75
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.7M 0.22%
8,447
+556
+7% +$122K
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ikarian Capital held 222 positions worth $760M, up 13% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital deployed $192M of net new capital in Q1 2022, opening 36 new positions and adding to 135 existing holdings. Its largest new stake was Sage Therapeutics: 249,907 shares worth $8.27M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 51% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $10.1M trimmed.

  • Ikarian Capital's largest Q1 2022 buy was Sage Therapeutics: 249,907 shares worth $8.27M.
  • Ikarian Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $5.56M increase.
  • Ikarian Capital's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $10.1M.
  • Ikarian Capital fully exited iShares Biotechnology ETF in Q1 2022, selling an estimated $3.67M.
  • Ikarian Capital's ten largest holdings make up 39% of its $760M portfolio in Q1 2022.
  • Ikarian Capital opened 36 new positions and closed 26 in Q1 2022.
  • Ikarian Capital's portfolio value rose 13% quarter-over-quarter to $760M.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.